Metformin, but not sitagliptin, enhances WP 631-induced apoptotic HepG2 cell death

Toxicology in Vitro

Volumn 29, Issue 5, 2015, Pages 1116-1123

  Sliwinska, Agnieszka ^a   Rogalska, Aneta ^b   Marczak, Agnieszka ^b   Kasznicki, Jacek ^a   Drzewoski, Jozef ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF LODZ   (Poland)

Author keywords

Apoptosis; Hepatocarcinoma; Metformin; Sitagliptin; WP 631

Indexed keywords

3',3' N XYLENYLBIS(DAUNORUBICIN); IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METFORMIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; SITAGLIPTIN; ANTIDIABETIC AGENT; DAUNORUBICIN;

ANALYSIS OF VARIANCE; ANTIBODY DETECTION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOTINYLATION; CELL DEATH; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME INACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UBIQUITINATION; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; DRUG EFFECTS; HEPG2 CELL LINE; METABOLISM;

APOPTOSIS; DAUNORUBICIN; HEP G2 CELLS; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; NF-KAPPA B; SITAGLIPTIN PHOSPHATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84938519789     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2015.04.019     Document Type: Article

References (37)

1. Ak P., Levine A.J. P53 and NF-κB: different strategies for responding to stress lead to a functional antagonism. FASEB. J. 2010, 24:3643-3652.
2. Ashikawa K., Shishodia S., Fokt I., Priebe W., Aggarwal B.B. Evidence that activation of nuclear factor-kappaB is essential for the cytotoxic effects of doxorubicin and its analogues. Biochem. Pharmacol. 2004, 67:353-364.
3. Bai D., Ueno L., Vogt P.K. Akt-mediated regulation of NFkappaB and the essentialness of NFkappaB for the oncogenicity of PI3K and Akt. Int. J. Cancer 2009, 125:2863-2870.
4. Buac D., Kona F.R., Seth A.K., Dou Q.P. Regulation of metformin response by breast cancer associated gene 2. Neoplasia 2013, 15:1379-1390.
5. Cai X., Hu X., Cai B., Wang Q., Li Y., Tan X., Hu H., Chen X., Huang J., Cheng J., Jing X. Metformin suppresses hepatocellular carcinoma cell growth through induction of cell cycle G1/G0 phase arrest and p21CIP and p27KIP expression and downregulation of cyclin D1 in vitro and in vivo. Oncol. Rep. 2013, 30:2449-2457.
6. Campbell K.J., Rocha S., Perkins N.D. Active repression of antiapoptotic gene expression by RelA(p65) NF-kappa B. Mol. Cell. 2004, 13:853-865.
7. Carmichael J., DeGraff W.G., Gazdar A.F., Minna J.D., Mitchell J.B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 1987, 47:936-942.
8. Chen G., Xu S., Renko K., Derwahl M. Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. J. Clin. Endocrinol. Metab. 2012, 97:E510-E520.
9. Chen H.P., Shieh J.J., Chang C.C., Chen T.T., Lin J.T., Wu M.S., Lin J.H., Wu C.Y. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 2013, 62:606-615.
10. Chen G., Nicula D., Renko K., Derwahl M. Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells. Oncol. Rep. 2015, 10.3892/or.2015.3805.
11. Dan H.C., Cooper M.J., Cogswell P.C., Duncan J.A., Ting J.P., Baldwin A.S. Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. Genes Dev. 2008, 22:1490-1500.
12. Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., Greenberg M.E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91:231-241.
13. Do M.T., Kim H.G., Choi J.H., Jeong H.G. Metformin induces microRNA-34a to downregulate the Sirt1/Pgc-1α/Nrf2 pathway, leading to increased susceptibility of wild-type p53 cancer cells to oxidative stress and therapeutic agents. Free. Radic. Biol. Med. 2014, 74:21-34.
14. Erices R., Bravo M.L., Gonzalez P., Oliva B., Racordon D., Garrido M., Ibañez C., Kato S., Brañes J., Pizarro J., Barriga M.I., Barra A., Bravo E., Alonso C., Bustamente E., Cuello M.A., Owen G.I. Metformin, at concentrations corresponding to the treatment of diabetes, potentiates the cytotoxic effects of carboplatin in cultures of ovarian cancer cells. Reprod. Sci. 2013, 20:1433-1446.
15. Femia A.P., Raimondi L., Maglieri G., Lodovici M., Mannucci E., Caderni G. Long-term treatment with Sitagliptin, a dipeptidyl peptidase-4 inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1,2-dimethylhydrazine-induced rats. Int. J. Cancer 2013, 133:2498-2503.
16. Gajek A., Denel M., Bukowska B., Rogalska A., Marczak A. Pro-apoptotic activity of new analog of anthracyclines - WP 631 in advanced ovarian cancer cell line. Toxicol. In Vitro 2014, 28:273-281.
17. Hirsch H.A., Iliopoulos D., Tsichlis P.N., Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009, 69:7507-7751.
18. Huang T.T., Wuerzberger-Davis S.M., Wu Z.H., Miyamoto S. Sequential modification of NEMO/IKKgamma by SUMO-1 and ubiquitin mediates NF-kappaB activation by genotoxic stress. Cell 2003, 115:565-576.
19. Iliopoulos D., Hirsch H.A., Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res. 2011, 71:3196-3201.
20. Jang S.Y., Kim A., Kim J.K., Kim C., Cho Y.H., Kim J.H., Kim C.H., Lee J.Y. Metformin inhibits tumor cell migration via down-regulation of MMP9 in tamoxifen-resistant breast cancer cells. Anticancer. Res. 2014, 34:4127-4134.
21. Kasznicki J., Sliwinska A., Drzewoski J. Metformin in cancer prevention and therapy. Ann. Transl. Med. 2014, 2:57-67.
22. Kim H.G., Hien T.T., Han E.H., Hwang Y.P., Choi J.H., Kang K.W., Kwon K.I., Kim B.H., Kim S.K., Song G.Y., Jeong T.C., Jeong H.G. Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation. Br. J. Pharmacol. 2011, 162:1096-1108.
23. Kim E.H., Kim M.S., Cho C.K., Jung W.G., Jeong Y.K., Jeong J.H. Low and high linear energy transfer radiation sensitization of HCC cells by metformin. J. Radiat. Res. 2014, 55:432-442.
24. Lenski M., Kazakov A., Marx N., Böhm M., Laufs U. Effects of DPP-4 inhibition on cardiac metabolism and function in mice. J. Mol. Cell. Cardiol. 2011, 51:906-918.
25. Liu H., Scholz C., Zang C., Schefe J.H., Habbel P., Regierer A.C., Schulz C.O., Possinger K., Eucker J. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. Anticancer Res. 2012, 32:1627-1637.
26. Mukherjee A., Misra S., Howlett N.G., Karmakar P. Multinucleation regulated by the Akt/PTEN signaling pathway is a survival strategy for HepG2 cells. Mutat. Res. 2013, 755:135-140.
27. Nelson L.E., Valentine R.J., Cacicedo J.M., Gauthier M.S., Ido Y., Ruderman N.B. A novel inverse relationship between metformin-triggered AMPK-SIRT1 signaling and p53 protein abundance in high glucose-exposed HepG2 cells. Am. J. Physiol. Cell Physiol. 2012, 303:C4-C13.
28. Nerenstone S., Friedman M. Medical treatment of hepatocellular carcinoma. Gastroenterol. Clin. North. Am. 1987, 16:603-612.
29. Nilsson S., Huelsenbeck J., Fritz G. Mevalonate pathway inhibitors affect anticancer drug-induced cell death and DNA damage response of human sarcoma cells. Cancer Lett. 2011, 304:60-69.
30. Ogawara Y., Kishishita S., Obata T., Isazawa Y., Suzuki T., Tanaka K., Masuyama N., Gotoh Y. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J. Biol. Chem. 2002, 277:21843-21850.
31. Oz Gul O., Cinkilic N., Gul C.B., Cander S., Vatan O., Ersoy C., Yilmaz D., Tuncel E. Comparative genotoxic and cytotoxic effects of the oral antidiabetic drugs sitagliptin, rosiglitazone, and pioglitazone in patients with type-2 diabetes: a cross-sectional, observational pilot study. Mutat. Res. 2013, 757:31-35.
32. Rogalska A., Gajek A., Szwed M., Jóźwiak Z., Marczak A. The role of reactive oxygen species in WP 631-induced death of human ovarian cancer cells: a comparison with the effect of doxorubicin. Toxicol. In Vitro 2011, 25:1712-1720.
33. Ryan K.M., Ernst M.K., Rice N.R., Vousden K.H. Role of NF-kappaB in p53-mediated programmed cell death. Nature 2000, 404:892-897.
34. Shi W.Y., Xiao D., Wang L., Dong L.H., Yan Z.X., Shen Z.X., Chen S.J., Chen Y., Zhao W.L. Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy. Cell Death Dis. 2012, 3:275.
35. Stambolic V., Suzuki A., de la Pompa J.L., Brothers G.M., Mirtsos C., Sasaki T., Ruland J., Penninger J.M., Siderovski D.P., Mak T.W. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998, 95:29-39.
36. Vujic I., Sanlorenzo M., Posch C., Esteve-Puig R., Yen A.J., Kwong A., Tsumura A., Murphy R., Rappersberger K., Ortiz-Urda S. Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer. Oncotarget 2015, 6:969-978.
37. Yoshida S., Hong S., Suzuki T., Nada S., Mannan A.M., Wang J., Okada M., Guan K.L., Inoki K. Redox regulates mammalian target of rapamycin complex 1 (mTORC1) activity by modulating the TSC1/TSC2-Rheb GTPase pathway. J. Biol. Chem. 2011, 286:32651-32660.